How are the world’s largest pharmaceutical companies adapting their R&D strategies to incorporate new technology that is putting the emphasis back on the patient?
Mobile health (mHealth) is just beginning to influence drug development.
Pharma's sentiment that the federal government’s policies perpetually lag behind innovations pioneered by the private sector has resulted in a vicious cycle of stagnated progress.
Pharma is due for disruption and tech seems ready to deliver it.
How will value-based healthcare be reflected in the pharma, medical and insurance industries?